ClinicalTrials.gg
CompletedNCT04477486Updated Aug 28, 2026Results posted

Study to Assess Effect of Oral Venetoclax Tablet in Combination With Oral Ibrutinib Capsule on Best Overall Response of Complete Response in Adult Japanese Participants With Relapsed/Refractory Mantle Cell Lymphoma

A Phase 2 interventional study of Ibrutinib and Venetoclax in Mantle Cell Lymphoma (MCL), sponsored by AbbVie. Completed at 12 sites in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2026-08-28.

Sponsored by AbbVie · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
13
Allocation
Not applicable
Ages
20 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 45 studies testing ibrutinib in Lymphoma, Mantle-Cell — 2 open to participants now, 16 under way, 2 of them phase 3. ibrutinib · Lymphoma, Mantle-Cell.

Enrollment
36th of 45
13 · median 39
Started
2020
with 3 others
Phase 2
21 of 45
none open now
Registered
39th of 45
by date
Lead sponsor
1 of 45
AbbVie

Among the 45 studies testing ibrutinib in Lymphoma, Mantle-Cell, this one is the 36th largest by enrollment, is one of 4 that started in 2020, is one of 21 in phase 2, and was the 39th registered.

Lymphoma, Mantle-Cell

1,221 studies on the registry are indexed under Lymphoma, Mantle-Cell; 154 are open to participants now.

Browse Lymphoma, Mantle-Cell studies →

Open to participants now

2 of the 45 studies testing ibrutinib in Lymphoma, Mantle-Cell are open now, in 6 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About ibrutinib

ibrutinib: first FDA approval 2013 (IMBRUVICA), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 125 Lymphoma, Mantle-Cell studies recruiting now, 92 (74%) set no upper age limit and 12 (10%) stop at 75 or younger; 14 take children under 18; 2 take healthy volunteers.

This study: 20 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 45 studies testing ibrutinib in Lymphoma, Mantle-Cell, or all of them as a file.
02

Study summary

Mantle Cell Lymphoma (MCL) is a form of Non-Hodgkin Lymphoma (NHL - cancer of the lymphatic system in blood) where cells from outer edge of the lymph nodes, called mantle zone become cancerous. In Japan, MCL accounts for about 3% of all NHL cases. Symptoms of MCL may include enlarged lymph nodes, stomach pain, fever, night sweats, and weight loss. Currently, MCL is not curable with standard therapies. The purpose of this study is to evaluate the safety, efficacy, and effect of venetoclax in combination with ibrutinib on best overall response of complete response in participants with relapsed (return of disease) or refractory (not responding to treatment) (R/R) MCL.

Venetoclax is an investigational drug being developed for the treatment of MCL. Ibrutinib is a drug approved for the treatment of MCL. Participants will receive venetoclax (increasing doses) and ibrutinib (fixed dose) for approximately 104 weeks, followed by ibrutinib alone. Adult participants with R/R MCL will be enrolled. Around 12 participants will be enrolled in Japan.

Participants will receive oral venetoclax tablet and oral ibrutinib capsule for 104 weeks. After 104 weeks, participants will receive ibrutinib once daily until their disease progresses, or they cannot tolerate the medication, or until they do not want to participate in the study.

There may be a higher treatment burden for participants in this study compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, bone marrow biopsies, checking for side effects, and completing questionnaires.

03

Conditions studied

  • Mantle Cell Lymphoma (MCL)

Keywords

  • MCL
  • Venetoclax
  • ABT-199
  • Ibrutinib
  • Imbruvica
04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • confirmed Mantle Cell Lymphoma (MCL) (tumor tissue) by local testing.
  • At least 1 measurable site of disease on cross-sectional imaging that is >= 2.0 centimeters (cm) in the longest diameter and measurable in 2 perpendicular dimensions per Computed Tomography (CT).
  • At least 1, but no more than 5, prior treatment regimens for MCL including at least 1 prior rituximab/anti-CD20 containing regimen.
  • Failure to achieve at least partial response (PR) with, or documented disease progression after, the most recent treatment regimen.

Exclusion criteria

Exclusion Criteria:

  • Prior therapy with ibrutinib or other Bruton Tyrosine Kinase (BTK) inhibitors.
  • History of other , except:

    • Malignancy treated with curative intent and with no known active disease present for >= 3 years before the first dose of study drug and felt to be at low risk for recurrence by treating physician.
    • Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease.
    • Adequately treated carcinoma in situ without evidence of disease.
  • History or current evidence of central nervous system lymphoma.
  • Treatment with any of the following within 7 days prior to the first dose of study drug:

    • Moderate or strong cytochrome P450 3A () inhibitors.
    • Moderate or strong CYP3A inducers.
    • Anticancer therapy, including chemotherapy, radiotherapy, small molecule, and agents, and/or monoclonal antibody \<=21 days prior to the first dose of study drug.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
13 participants (actual)

Study arms

  • Experimental
    Ibrutinib + Venetoclax

    Participants will receive Ibrutinib Dose A + Venetoclax in various doses until a target dose is reached, for up to 104 weeks, followed by Ibrutinib monotherapy.

    Drug: Ibrutinib · Drug: Venetoclax

Interventions

  • Capsule; Oral

    Also known as: Imbruvica

  • Tablet; Oral

    Also known as: ABT-199, Venclexta, GDC-0199, Venclyxto

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Achieving Best Overall Response of Complete Response (CR), as Assessed by the Independent Review Committee (IRC)

    Complete response rate (CRR), defined as the percentage of participants achieving a best overall response of complete response (CR) per the Revised Criteria for Response Assessment for Malignant Lymphoma following the Lugano classification (Cheson 2014), assessed by an Independent Review Committee (IRC).

    Time frame: Week 13

Secondary outcomes

  1. Percentage of Participants Achieving Best Overall Response of CR or PR, as Assessed by the IRC

    Overall Response Rate (ORR), defined as the percentage of participants with a best overall response of CR or PR, per the Revised Criteria for Response Assessment for Malignant Lymphoma, assessed by an Independent Review Committee (IRC).

    Time frame: Median follow-up time of 48 months (range: 2.3 to 50.7)

  2. Percentage of Participants Achieving Best Overall Response of CR as Assessed by the Investigator

    Best overall response of CR is defined as the percentage of participants achieving a best overall response of CR for the venetoclax and ibrutinib combination, as assessed by the investigator per the Revised Criteria for Response Assessment for Malignant Lymphoma .

    Time frame: Median follow-up time of 48 months (range: 2.3 to 50.7)

  3. Percentage of Participants Achieving Best Overall Response of CR or PR, as Assessed by the Investigator

    Best overall response of CR or PR will be evaluated using ORR. The ORR is defined as the percentage of participants with a best overall response of CR or PR, according to the Revised Criteria for Response Assessment for Malignant Lymphoma, as assessed by the investigator.

    Time frame: Median follow-up time of 48 months (range: 2.3 to 50.7)

  4. Duration of Response (DOR) for Participants Who Achieved a Best Overall Response of CR or PR, as Assessed by the Investigator

    DOR is defined as the time from the first occurrence of response (CR or PR) to disease progression or death, whichever occurs first, according to the Revised Criteria for Response Assessment for Malignant Lymphoma, as assessed by the investigator.

    Time frame: Median follow-up time of 48 months (range: 2.3 to 50.7)

  5. DOR for Participants Who Achieved a Best Overall Response of CR or PR, as Assessed by the IRC

    DOR is defined as the time from the first occurrence of response (CR or PR) to disease progression or death, whichever occurs first, according to the Revised Criteria for Response Assessment for Malignant Lymphoma, as assessed by the IRC.

    Time frame: Median follow-up time of 48 months (range: 2.3 to 50.7)

  6. Undetectable Minimal Residual Disease (uMRD) in Peripheral Blood in Participants Who Achieve a Best Overall Response of CR as Assessed by the Investigator and the IRC

    MRD rate is defined as the percentage of participants with uMRD who achieve a best overall response of CR, according to the Revised Criteria for Response Assessment for Malignant Lymphoma, as assessed by the investigator.

    Time frame: Median follow-up time of 48 months (range: 2.3 to 50.7)

  7. uMRD in Bone Marrow Participants Who Achieve a Best Overall Response of CR as Assessed by the Investigator and the IRC.

    MRD rate is defined as the percentage of participants with uMRD who achieve a best overall response of CR, according to the Revised Criteria for Response Assessment for Malignant Lymphoma, as assessed by investigator and the IRC.

    Time frame: Median follow-up time of 48 months (range: 2.3 to 50.7)

  8. Progression-Free Survival (PFS)

    PFS is defined as the time from the date of the first dose of study drug (venetoclax or ibrutinib) to the date of investigator-assessed disease progression, using the Revised Response Criteria for Response Assessment for Malignant Lymphoma, or death from any cause, whichever occurs first.

    Time frame: Median follow-up time of 48 months (range: 2.3 to 50.7)

  9. Overall Survival (OS)

    OS is defined as the time from the date of the first dose of the study drug (venetoclax or ibrutinib) to death from any cause.

    Time frame: Median follow-up time of 48 months (range: 2.3 to 50.7)

07

Results

Posted Jan 14, 2025

Participant flow

A total of 13 participants were enrolled across 8 sites in Japan. The study was not considered terminated because, after venetoclax plus ibrutinib combination therapy was approved in Japan for relapsed/refractory mantle cell lymphoma, the remaining participants transitioned to commercially available drug supply or other available treatment options. As specified in the protocol, the study was therefore considered discontinued rather than terminated.

Participant flow — Overall Study
MilestoneIbrutinib + Venetoclax
Started13
Completed0
Not completed13
Withdrew: Death5
Withdrew: Discontinued study - study terminated by sponsor8

Outcome measures

PrimaryPercentage of Participants Achieving Best Overall Response of Complete Response (CR), as Assessed by the Independent Review Committee (IRC)

Complete response rate (CRR), defined as the percentage of participants achieving a best overall response of complete response (CR) per the Revised Criteria for Response Assessment for Malignant Lymphoma following the Lugano classification (Cheson 2014), assessed by an Independent Review Committee (IRC).

Time frame:
Week 13
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Best Overall Response of Complete Response (CR), as Assessed by the Independent Review Committee (IRC)
percentage of participantsIbrutinib + Venetoclax
Percentage of Participants Achieving Best Overall Response of Complete Response (CR), as Assessed by the Independent Review Committee (IRC)83.3 (51.6 to 97.9)
Statistical analysis
  • Ibrutinib + Venetoclax · Exact Binomial Distribution · p = <0.001
SecondaryPercentage of Participants Achieving Best Overall Response of CR or PR, as Assessed by the IRC

Overall Response Rate (ORR), defined as the percentage of participants with a best overall response of CR or PR, per the Revised Criteria for Response Assessment for Malignant Lymphoma, assessed by an Independent Review Committee (IRC).

Time frame:
Median follow-up time of 48 months (range: 2.3 to 50.7)
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Best Overall Response of CR or PR, as Assessed by the IRC
percentage of participantsIbrutinib + Venetoclax
Percentage of Participants Achieving Best Overall Response of CR or PR, as Assessed by the IRC83.3 (51.6 to 97.9)
SecondaryPercentage of Participants Achieving Best Overall Response of CR as Assessed by the Investigator

Best overall response of CR is defined as the percentage of participants achieving a best overall response of CR for the venetoclax and ibrutinib combination, as assessed by the investigator per the Revised Criteria for Response Assessment for Malignant Lymphoma .

Time frame:
Median follow-up time of 48 months (range: 2.3 to 50.7)
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Best Overall Response of CR as Assessed by the Investigator
percentage of participantsIbrutinib + Venetoclax
Percentage of Participants Achieving Best Overall Response of CR as Assessed by the Investigator76.9 (46.2 to 95.0)
SecondaryPercentage of Participants Achieving Best Overall Response of CR or PR, as Assessed by the Investigator

Best overall response of CR or PR will be evaluated using ORR. The ORR is defined as the percentage of participants with a best overall response of CR or PR, according to the Revised Criteria for Response Assessment for Malignant Lymphoma, as assessed by the investigator.

Time frame:
Median follow-up time of 48 months (range: 2.3 to 50.7)
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Best Overall Response of CR or PR, as Assessed by the Investigator
percentage of participantsIbrutinib + Venetoclax
Percentage of Participants Achieving Best Overall Response of CR or PR, as Assessed by the Investigator76.9 (46.2 to 95.0)
SecondaryDuration of Response (DOR) for Participants Who Achieved a Best Overall Response of CR or PR, as Assessed by the Investigator

DOR is defined as the time from the first occurrence of response (CR or PR) to disease progression or death, whichever occurs first, according to the Revised Criteria for Response Assessment for Malignant Lymphoma, as assessed by the investigator.

Time frame:
Median follow-up time of 48 months (range: 2.3 to 50.7)
Reported as:
Median · months
Duration of Response (DOR) for Participants Who Achieved a Best Overall Response of CR or PR, as Assessed by the Investigator
monthsIbrutinib + Venetoclax
Duration of Response (DOR) for Participants Who Achieved a Best Overall Response of CR or PR, as Assessed by the InvestigatorNA (18.5 to NA)
SecondaryDOR for Participants Who Achieved a Best Overall Response of CR or PR, as Assessed by the IRC

DOR is defined as the time from the first occurrence of response (CR or PR) to disease progression or death, whichever occurs first, according to the Revised Criteria for Response Assessment for Malignant Lymphoma, as assessed by the IRC.

Time frame:
Median follow-up time of 48 months (range: 2.3 to 50.7)
Reported as:
Median · months
DOR for Participants Who Achieved a Best Overall Response of CR or PR, as Assessed by the IRC
monthsIbrutinib + Venetoclax
DOR for Participants Who Achieved a Best Overall Response of CR or PR, as Assessed by the IRC45.2 (45.0 to NA)
SecondaryUndetectable Minimal Residual Disease (uMRD) in Peripheral Blood in Participants Who Achieve a Best Overall Response of CR as Assessed by the Investigator and the IRC

MRD rate is defined as the percentage of participants with uMRD who achieve a best overall response of CR, according to the Revised Criteria for Response Assessment for Malignant Lymphoma, as assessed by the investigator.

Time frame:
Median follow-up time of 48 months (range: 2.3 to 50.7)
Reported as:
Number · percentage of participants
Undetectable Minimal Residual Disease (uMRD) in Peripheral Blood in Participants Who Achieve a Best Overall Response of CR as Assessed by the Investigator and the IRC
percentage of participantsIbrutinib + Venetoclax
Peripheral Blood (Per Investigator)100 (54.1 to 100)
Peripheral Blood (Per IRC)100 (54.1 to 100)
SecondaryuMRD in Bone Marrow Participants Who Achieve a Best Overall Response of CR as Assessed by the Investigator and the IRC.

MRD rate is defined as the percentage of participants with uMRD who achieve a best overall response of CR, according to the Revised Criteria for Response Assessment for Malignant Lymphoma, as assessed by investigator and the IRC.

Time frame:
Median follow-up time of 48 months (range: 2.3 to 50.7)
Reported as:
Number · percentage of participants
uMRD in Bone Marrow Participants Who Achieve a Best Overall Response of CR as Assessed by the Investigator and the IRC.
percentage of participantsIbrutinib + Venetoclax
Bone Marrow (Per Investigator)100 (15.8 to 100)
Bone Marrow (Per IRC)100 (15.8 to 100)
SecondaryProgression-Free Survival (PFS)

PFS is defined as the time from the date of the first dose of study drug (venetoclax or ibrutinib) to the date of investigator-assessed disease progression, using the Revised Response Criteria for Response Assessment for Malignant Lymphoma, or death from any cause, whichever occurs first.

Time frame:
Median follow-up time of 48 months (range: 2.3 to 50.7)
Reported as:
Median · months
Progression-Free Survival (PFS)
monthsIbrutinib + Venetoclax
Progression-Free Survival (PFS)43.4 (22.6 to NA)
SecondaryOverall Survival (OS)

OS is defined as the time from the date of the first dose of the study drug (venetoclax or ibrutinib) to death from any cause.

Time frame:
Median follow-up time of 48 months (range: 2.3 to 50.7)
Reported as:
Median · months
Overall Survival (OS)
monthsIbrutinib + Venetoclax
Overall Survival (OS)48.2 (24.5 to NA)

Adverse events

Collected over All-cause mortality and adverse event tables include events reported from enrollment to the end of the study. The median time participants were followed was 209 weeks.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Ibrutinib + Venetoclax5/13 (38.5%)7/13 (53.8%)13/13 (100%)
Most frequent serious events
Showing 10 of 22
Most frequent serious events
EventIbrutinib + Venetoclax
PYREXIAGeneral disorders2/13
COVID-19 PNEUMONIAInfections and infestations2/13
NEUTROPENIABlood and lymphatic system disorders1/13
GLAUCOMAEye disorders1/13
HAEMORRHOIDSGastrointestinal disorders1/13
LOWER GASTROINTESTINAL HAEMORRHAGEGastrointestinal disorders1/13
PANCREATITISGastrointestinal disorders1/13
BILE DUCT STENOSISHepatobiliary disorders1/13
COVID-19Infections and infestations1/13
INTERVERTEBRAL DISCITISInfections and infestations1/13
Most frequent other events
Showing 10 of 114
Most frequent other events
EventIbrutinib + Venetoclax
DIARRHOEAGastrointestinal disorders7/13
LEUKOPENIABlood and lymphatic system disorders5/13
NEUTROPENIABlood and lymphatic system disorders5/13
CONSTIPATIONGastrointestinal disorders5/13
THROMBOCYTOPENIABlood and lymphatic system disorders4/13
ATRIAL FIBRILLATIONCardiac disorders4/13
PYREXIAGeneral disorders4/13
SKIN INFECTIONInfections and infestations4/13
ANAEMIABlood and lymphatic system disorders3/13
NAUSEAGastrointestinal disorders3/13

Baseline characteristics

Full Analysis Set (N=13)

Age, Categorical
Age, Categorical(Participants)Ibrutinib + Venetoclax
<=18 years0
Between 18 and 65 years2
>=65 years11
Age, Continuous
Age, Continuous(Years)Ibrutinib + Venetoclax
Mean69.8 ± 5.97
Sex: Female, Male
Sex: Female, Male(Participants)Ibrutinib + Venetoclax
Female3
Male10
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Ibrutinib + Venetoclax
Hispanic or Latino0
Not Hispanic or Latino13
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Ibrutinib + Venetoclax
American Indian or Alaska Native0
Asian13
Native Hawaiian or Other Pacific Islander0
Black or African American0
White0
More than one race0
Unknown or Not Reported0
Region of Enrollment
Region of Enrollment(participants)Ibrutinib + Venetoclax
Japan13
08

Study locations

12 sites
  • NHO Nagoya Medical Center /ID# 221958
    Nagoya, Aichi-ken 460-0001, Japan
  • Aichi Cancer Center Hospital /ID# 221565
    Nagoya, Aichi-ken 464-8681, Japan
  • Kyushu University Hospital /ID# 223299
    Fukuoka, Fukuoka 812-8582, Japan
  • National Hospital Organization Mito Medical Center /ID# 224912
    Ibaraki, Higashiibaraki 311-3193, Japan
  • Hokkaido University Hospital /ID# 221662
    Sapporo, Hokkaido 060-8648, Japan
  • Kobe City Medical Center General Hospital /ID# 221744
    Kobe, Hyōgo 650-0047, Japan
  • Ishikawa Prefectural Central Hospital /ID# 224896
    Kanazawa, Ishikawa-ken 920-8530, Japan
  • Tohoku University Hospital /ID# 221975
    Sendai, Miyagi 9808574, Japan
  • Duplicate_Okayama University Hospital /ID# 221623
    Okayama, Okayama-ken 700-8558, Japan
  • Saitama Medical Center /ID# 224910
    Kawagoe-shi, Saitama 350-8550, Japan
  • National Cancer Center Hospital /ID# 221812
    Chuo-ku, Tokyo 104-0045, Japan
  • Yamagata University Hospital /ID# 221573
    Yamagata, Yamagata 990-9585, Japan
09

References and documents

Related links

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — AbbVie is committed to responsible clinical trial data sharing. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: For details on when studies are available for sharing visit https://vivli.org/ourmember/abbvie/

Access criteria: To learn more about the process, or to submit a request, visit the following link https://www.abbvieclinicaltrials.com/hcp/data-sharing/

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2020 to primary completion in Feb 2022, 16 months.

Results were first posted in Jan 2025, 2 years 11 months after primary completion. A results delay was requested in Dec 2022.

Of 30 industry-sponsored phase 2 interventional studies under Lymphoma, Mantle-Cell, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 87. This study's 16 months is below that.

Counting every sponsor, half of 183 studies reached it within 63 months; a quarter within 38 and three quarters within 106.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 17, 2020
First posted
Jul 20, 2020
StartActual
Sep 23, 2020
Primary completionActual
Feb 9, 2022
CompletionActual
May 28, 2025
Results delay requested
Dec 21, 2022
Results first posted
Jan 14, 2025
Last update
Aug 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 28, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04477486
Lead sponsor
AbbVie
Responsible party
Sponsor
First posted
Jul 20, 2020
Start date
Sep 23, 2020
Primary completion
Feb 9, 2022
Completion
May 28, 2025
Results posted
Jan 14, 2025
Last update
Aug 28, 2026

Study contacts

ABBVIE INC.
study director · AbbVie

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Ibrutinib · Venetoclax

Start the discussion